ES2370040T3 - Vacuna de metaloproteinasa 11 de la matriz. - Google Patents

Vacuna de metaloproteinasa 11 de la matriz. Download PDF

Info

Publication number
ES2370040T3
ES2370040T3 ES06792355T ES06792355T ES2370040T3 ES 2370040 T3 ES2370040 T3 ES 2370040T3 ES 06792355 T ES06792355 T ES 06792355T ES 06792355 T ES06792355 T ES 06792355T ES 2370040 T3 ES2370040 T3 ES 2370040T3
Authority
ES
Spain
Prior art keywords
mmp
polypeptide
encoding
ltb
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06792355T
Other languages
English (en)
Spanish (es)
Inventor
Luigi Aurisicchio
Nicola La Monica
Gennaro Ciliberto
Domenico Lazzaro
Federica Mori
Daniela Peruzzi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Original Assignee
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto di Ricerche di Biologia Molecolare P Angeletti SpA filed Critical Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Application granted granted Critical
Publication of ES2370040T3 publication Critical patent/ES2370040T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/6416—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
ES06792355T 2005-10-07 2006-10-03 Vacuna de metaloproteinasa 11 de la matriz. Active ES2370040T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72449805P 2005-10-07 2005-10-07
US724498P 2005-10-07

Publications (1)

Publication Number Publication Date
ES2370040T3 true ES2370040T3 (es) 2011-12-12

Family

ID=37451271

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06792355T Active ES2370040T3 (es) 2005-10-07 2006-10-03 Vacuna de metaloproteinasa 11 de la matriz.

Country Status (9)

Country Link
US (2) US8106176B2 (enExample)
EP (1) EP1934246B8 (enExample)
JP (1) JP5361386B2 (enExample)
CN (1) CN101365715B (enExample)
AT (1) ATE521629T1 (enExample)
AU (1) AU2006301582B2 (enExample)
CA (1) CA2623531C (enExample)
ES (1) ES2370040T3 (enExample)
WO (1) WO2007042169A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
PT2340031T (pt) 2008-08-14 2019-07-25 Acceleron Pharma Inc Armadilhas de gdf para uso no tratamento de anemia
EP2342334A4 (en) * 2008-09-29 2012-03-14 Univ Pennsylvania VACCINES DIRECTED TO TUMOR VESSEL MARKERS
CN102482339B (zh) 2009-06-08 2015-06-17 阿塞勒隆制药公司 用于增加产热脂肪细胞的方法
RU2642302C1 (ru) * 2009-08-13 2018-01-24 Акселерон Фарма Инк. Комбинированное применение ловушек gdf и активаторов рецепторов эритропоэтина для повышения содержания эритроцитов
CN107028886A (zh) 2009-11-04 2017-08-11 不列颠哥伦比亚大学 含有核酸的脂质粒子及相关的方法
EP2770980A4 (en) 2011-10-25 2015-11-04 Univ British Columbia LOW SIZE LIPID NANOPARTICLES AND METHODS THEREOF
EP2971013B1 (en) 2013-03-15 2020-08-19 The University Of British Columbia Lipid nanoparticles for transfection and related methods
PH12021550850A1 (en) 2015-03-27 2022-10-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various tumors
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
WO2018156106A1 (en) * 2017-02-22 2018-08-30 Ding Enyu An mrna cancer vaccine encoding human gm-csf fused to multiple tandem epitopes
CN115003820A (zh) * 2019-10-08 2022-09-02 爱科霍拉有限公司 用于眼部治疗的组合物和方法
WO2022220603A1 (ko) 2021-04-16 2022-10-20 고려대학교 산학협력단 코로나-19 바이러스 표적 인간 항체
GB202117583D0 (en) * 2021-12-06 2022-01-19 Cambridge Entpr Ltd Protein expression
CN116590263A (zh) * 2023-07-02 2023-08-15 广州庆毅生物医药科技有限公司 一种重组蛋白、单克隆抗体及其检测试剂盒和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78775A (en) * 1985-05-15 1992-06-21 Biotech Australia Pty Ltd Oral vaccines
GB9112553D0 (en) 1991-06-11 1991-07-31 Wellcome Found Fusion proteins
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
US5945399A (en) * 1996-05-23 1999-08-31 Xoma Corporation Therapeutic uses of BPI protein products in humans with hemorrhage due to trauma
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
CA2369058A1 (en) 1999-04-26 2000-11-02 K.U. Leuven Research & Development Synthetic gene for expressing active retroviral protein in eukaryotes
JP2003511061A (ja) * 1999-10-08 2003-03-25 アクティブ バイオテック エイビー 変更された化学結合体化特性を有するａｂ５毒素ｂサブユニット変異体
GB9930768D0 (en) * 1999-12-29 2000-02-16 Pfizer Ltd Composition
CA2422882A1 (en) 2000-09-15 2002-03-21 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
US20040110152A1 (en) * 2002-12-10 2004-06-10 Isis Pharmaceuticals Inc. Modulation of matrix metalloproteinase 11 expression
GB0321615D0 (en) * 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
MXPA06003977A (es) * 2003-10-10 2006-06-27 Powderject Vaccines Inc Metodo.
BRPI0507579A (pt) 2004-02-11 2007-07-03 Angeletti P Ist Richerche Bio molécula de ácido nucleico, vetor, célula hospedeira, processo para expressar uma proteìna de fusão cea em uma célula hospedeira recombinante, proteìna de fusão cea purificada, método de prevenção ou tratamento de cáncer, plasmìdeo de vacina, e, método de tratamento de um mamìfero sofrendo de ou predisposto a um cáncer associados com cea

Also Published As

Publication number Publication date
CA2623531C (en) 2013-12-10
CA2623531A1 (en) 2007-04-19
JP5361386B2 (ja) 2013-12-04
US20090155298A1 (en) 2009-06-18
WO2007042169A2 (en) 2007-04-19
AU2006301582A1 (en) 2007-04-19
CN101365715A (zh) 2009-02-11
EP1934246A2 (en) 2008-06-25
AU2006301582B2 (en) 2011-10-13
EP1934246B8 (en) 2012-02-08
US8106176B2 (en) 2012-01-31
ATE521629T1 (de) 2011-09-15
EP1934246B1 (en) 2011-08-24
WO2007042169A3 (en) 2007-05-31
JP2009509553A (ja) 2009-03-12
US20120177679A1 (en) 2012-07-12
US8492522B2 (en) 2013-07-23
CN101365715B (zh) 2013-03-27

Similar Documents

Publication Publication Date Title
US8492522B2 (en) Matrix metalloproteinase 11 vaccine
DK2155243T3 (en) Compositions and methods comprising KLK3, PSCA, or antigen FOLH1
US7446185B2 (en) Her2/neu target antigen and use of same to stimulate an immune response
ES2376010T3 (es) Prote�?na de fusión de transcriptasa inversa de la telomerasa, nucleótidos que la codifican y usos de la misma.
EP1804831B1 (en) Listeria-based and llo-based vaccines
US20140271724A1 (en) Methods and compositions for treating or preventing cancer
JP5148116B2 (ja) 癌胎児性抗原融合タンパク質及びその使用
CN110564751A (zh) 微环dna疫苗设计及应用
US20070104685A1 (en) Synthetic gene encoding human carcinoembryonic antigen and uses thereof
KR102158923B1 (ko) 암 백신
CN101001869B (zh) 癌胚抗原融合物和其用途
ZA200508013B (en) Synthetic gene encoding human carcinoembryonic antigen and use thereof
MXPA06009202A (en) Carcinoembryonic antigen fusions proteins and uses thereof
AU2006322645A1 (en) Treatment of Epstein-Barr Virus-associated diseases